Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women .
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2014;2(8):10 J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009.180 postmenopausal women with osteopenia were randomly allocated to receive either 1mg, 2.5 mg, or 5 mg intravenous infusion of zoledronate or a placebo. The purpose of this trial was to determine the optimal dosing regimen of zoledronate. Results indicated that a single administration of a 1 mg or 2.5 mg dose of intravenous zoledronate produces antiresorptive effects for at least two years, although the 1 mg antiresorptive effects appear to slow after 12 months. At 2 years post-intervention, the change in bone mineral density (BMD) and bone turnover markers in the 2.5 mg dose group were similar to effects induced by 5 mg.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Ja = 1
Ungewiss = 0.5
Nicht relevant = 0
Nein = 0
Die Bewertung der Berichtskriterien bewertet die Transparenz, mit der die Autoren die methodischen und studienspezifischen Merkmale der Studie in der Veröffentlichung angeben. Die Bewertung ist in fünf Kategorien unterteilt, die im Folgenden vorgestellt werden.
4/4
Randomization
4/4
Outcome Measurements
3/4
Inclusion / Exclusion
4/4
Therapy Description
3/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
Der Fragilitätsindex ist ein Instrument, das bei der Interpretation signifikanter Ergebnisse hilft und ein Maß für die Stärke eines Ergebnisses liefert. Der Fragilitätsindex gibt die Anzahl der aufeinanderfolgenden Ereignisse an, die zu einem dichotomen Ergebnis hinzugefügt werden müssen, damit das Ergebnis nicht mehr signifikant ist. Eine kleine Zahl steht für ein schwächeres Ergebnis und eine große Zahl für ein stärkeres Ergebnis.
Warum wurde diese Studie jetzt benötigt?
While it has been observed that annual intravenous administration of 5 mg of zoledronate may reduce the risk of fractures in osteoporosis patients and decrease mortality in hip fracture patients, the optimal dosing regimen of zoledronate remains ambiguous. Previously, it was found that a single administration of 1 mg and 2.5 mg zoledronate significantly decreased markers of bone turnover and increased bone mineral density after 1 year. Due to recent insight regarding potential long-term antiresorptive effects following single dose drug administration, the aim of this study was to investigate this topic at a follow-up of 2 years post-intervention.
Was war die wichtigste Forschungsfrage?
What are the effects of a single intravenous administration of either 1 mg, 2.5 mg, or 5 mg zoledronate on bone mineral density and bone turnover markers after 2 years?
- Bone mineral density (BMD) was higher in the zoledronate groups than the placebo group at each site and each time point during the trial (all p<0.0001).
- Change in lumbar spine BMD 2 years after a single administration of zoledronate was greater in the zoledronate groups than the placebo group, data expressed as mean (95% CI) percent difference than values in the placebo group [4.4% (2.7% to 6.1%) with 1 mg, 5.5% (3.9% to 7.2%) with 2.5 mg, and 5.3% (3.8% to 6.7%) with 5 mg] (for each dose, p<0.001).
- Change in total hip BMD 2 years after a single administration of zoledronate was greater in the zoledronate groups than the placebo group [2.6% (1.5% to 3.7%) with 1 mg, 4.4% (3.5% to 5.3%) with 2.5 mg; 4.7% (3.7% to 5.7%) with 5 mg] (for each dose, p<0.001).
- Change in the bone turnover marker Beta-CTX 2 years after a single administration of zoledronate was [-18% (-30% to -7%) with 1 mg, -45% (-54% to -35%) with 2.5 mg, and -51% (-60% to -42%) with 5 mg]. Throughout the trial the value of Beta-CTX in the 2.5 and 5 mg dose groups was significantly lower than the placebo group (p<0.0001). In the 1 mg dose group, the values of Beta-CTX were lower than placebo group values until 18 months.
- Change in the bone turnover marker P1NP 2 years after a single administration of zoledronate was [-15% (-26% to -4%) with 1 mg, -28% (-39% to -17%) with 2.5 mg, and -29% (-40% to -19%) with 5 mg]. Throughout the trial the value of P1NP in the 2.5 and 5 mg dose groups was significantly lower than the placebo group (p<0.0001). In the 1 mg dose group, P1NP values were lower than the placebo group, except at the two year time point.
- Comparison between zoledronate groups suggests the 2.5 mg zoledronate group produced changes in BMD and bone turnover markers which fell within +/- 1.5%, and +/- 15% of those observed in the 5 mg group, respectively. Contrarily, the 1-mg dose was not equivalent to the 5-mg dose for any of the BMD or turnover endpoints.
- In the zoledronate group, 1 participant developed iritis (with 5 mg), and 5 developed fractures (1 with 1 mg dose, 2 with 2.5 mg dose, 2 with 5 mg dose). In the placebo group, 3 participants developed fractures. No patient developed osteonecrosis of the jaw or suffered an atypical femoral fracture.
Was sollte ich mir besonders merken?
A single administration of 1 mg and 2.5 mg doses of intravenous zoledronate produced antiresorptive effects for at least two years, although the 1 mg antiresorptive effects appear to slow after 12 months. At 2 years post-intervention, the change in bone mineral density (BMD) and bone turnover markers in the 2.5 mg dose group were similar to effects induced by 5 mg.
Wie wird sich dies auf die Behandlung meiner Patienten auswirken?
Results from this study suggest that a single administration of 2.5 mg zoledronate may be equally effective in increasing total bone mineral density and decreasing bone turnover markers as a 5 mg dose. Caution must be exercised when considering comparative efficacy between these doses however; the study compared doses to placebo and not direct comparisons between doses. Direct comparisons are thus needed in future trials.
HAFTUNGSAUSSCHLUSS
Der Inhalt dieser Seite dient nur zu Informationszwecken und ist nicht als Ersatz für professionelle medizinische Beratung, Diagnose oder Behandlung gedacht. Wenn Sie eine medizinische Behandlung benötigen, wenden Sie sich immer an Ihren Arzt oder suchen Sie die nächstgelegene Notaufnahme auf. Die Meinungen, Überzeugungen und Standpunkte, die von den Personen auf dieser Seite geäußert werden, spiegeln nicht die Meinungen, Überzeugungen und Standpunkte von OrthoEvidence wider.
0 von 4 monatliche KOSTENLOSE Artikel freigeschaltet
